DRL in agreement with Eisai Co, Japan
Acquires rights to Investigational Anticancer Agent E7777 for US, Europe and certain emerging markets from Eisai
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Dr Reddy’s Laboratories
DRL in agreement with XenoPort
DRL will be granted exclusive US rights for the development and commercialisation of XenoPort’s clinical-stage oral new chemical…
DRL’s board approves proposal for buyback of its equity share
The buyback will be for an aggregate amount not exceeding Rs 15,694 million The Board of Directors of Dr Reddy’s Laboratories…
DRL receives US FDA approval for treatment of acute migraine episodes
ZEMBRACESymTouch is available as a prefilled, ready-to-use, single-dose disposable autoinjector containing 3 mg of sumatriptan US…
DRL signs MoU with LSSSDC and VIPER
The MoU is aimed at fostering market research collaboration that will help align educational courses to industry requirements
US FDA warns of serious data integrity violations at DRL
The US Food and Drug Administration has warned DRL over serious data integrity violations, placing all its new applications or…
DRL welcomes govt’s move on simplifying taxation laws
The company, however, wants deferment of sunset clause for SEZs Dr Reddy's Laboratories (DRL) has welcomed the government's…
Dr Reddy’s completes Fondaparinux IP purchase
The company had signed a term sheet for this transaction with its Australian partner, Alchemia in September 2015
Arogya Finance and DRL collaborate to provide medical loans for financially weak
Facilitates medical loans for Resof, a drug for treatment of Hepatitis C virus (HCV) infection and a few other therapies
DRL issues statement on receipt of warning letter from US FDA
The company has received warning letters for API manufacturing and oncology formulation manufacturing facilities at Andhra Pradesh…